🔥 Gate Square Event | #PostToWinLaunchpadKDK 🔥
KDK | The latest Gate Launchpad spotlight token
Before: stake USDT to join
Now 👉 just post for a chance to win KDK!
🎁 Gate Square exclusive: 2,000 KDK total rewards up for grabs
🚀 Launchpad star project — big potential ahead 👀
📅 Event Duration
Dec 19, 04:00 – Dec 30, 16:00 (UTC)
📌 How to Join
Post on Gate Square (text, images, analysis, or opinions)
Content should relate to KDK price predictions at launch, project insights, or your understanding of the Gate Launchpad mechanism
Add one hashtag: #发帖赢Launchpad新币KDK 或 #PostToWinLaunchpadKDK
�
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a “buy” rating.